Chilton Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Chilton Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.91K	Hold	13	–	–	﹤0.01%	509
2026 Q1	$4.3K	Buy	13 +12	+1,200%	+$4.08K	﹤0.01%	557
2025 Q4	$398	Buy	+1	New	+$443	﹤0.01%	652
2016 Q1	–	Sell	-4,605	Closed	-$434K	–	167
2015 Q4	$434K	Buy	+4,605	New	+$427K	0.05%	128

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chilton Capital Management's ALNY Position: Q2 2026 in Review

Chilton Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 13 shares worth $3.91K. The position accounts for ﹤0.01% of the portfolio, ranked #509.

Chilton Capital Management first reported a position in ALNY in Q4 2015 and has held it in 4 quarters since. The position peaked at $434K in Q4 2015. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Chilton Capital Management held 13 shares of Alnylam Pharmaceuticals worth $3.91K as of Q2 2026.
Chilton Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Chilton Capital Management's portfolio in Q2 2026, its #509 holding.
Chilton Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 4 quarters since.
Chilton Capital Management's Alnylam Pharmaceuticals position peaked at $434K in Q4 2015.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.